Susquehanna International Group
EVFM

Susquehanna International Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Susquehanna International Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,028,400
Closed -$1.16M – 14884
2022
Q2 		$1.16M Buy
1,028,400
+971,860
+1,719% +$1.6M ﹤0.01% 6156
2022
Q1 		$288K Buy
56,540
+10,440
+23% +$65.7K ﹤0.01% 10375
2021
Q4 		$263K Buy
46,100
+2,167
+5% +$18.4K ﹤0.01% 10807
2021
Q3 		$487K Sell
43,933
-1,400
-3% -$17.6K ﹤0.01% 9459
2021
Q2 		$768K Buy
45,333
+37,693
+493% +$715K ﹤0.01% 8487
2021
Q1 		$201K Sell
7,640
-547
-7% -$24.9K ﹤0.01% 11417
2020
Q4 		$296K Sell
8,187
-2,866
-26% -$104K ﹤0.01% 9285
2020
Q3 		$391K Buy
11,053
+2,846
+35% +$124K ﹤0.01% 8190
2020
Q2 		$348K Buy
+8,207
New +$553K ﹤0.01% 8089

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Susquehanna International Group's EVFM Position: Q2 2022 in Review

Susquehanna International Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 45,113 shares — an estimated $74.4K sold.

Susquehanna International Group first reported a position in EVFM in Q3 2017 and held it in 10 quarters. The position peaked at $1.48M in Q2 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Susquehanna International Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Susquehanna International Group sold 45,113 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $74.4K.
  • Susquehanna International Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
  • Susquehanna International Group's Evofem Biosciences, Inc. Common Stock position peaked at $1.48M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.